You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
大和:首予君實生物(1877.HK)目標價60港元 評級“優於大市”
格隆匯 10-19 14:08

大和發表研究報告指,預期君實生物(1877.HK)有參與其中的COVID-19中和抗體(JS016)的申請新藥上市(NDA)將於明年第二季獲批,或於明年第三季發行,料該藥高峯期將產生66億元人民幣收入,首予君實生物目標價60港元及“優於大市”評級。

大和表示,公司在研藥品管線廣泛覆蓋不同藥物,預期未來每一項藥品將能產生45億元人民幣的高峯期收入,料公司的非特瑞普利單抗(Toripalimab)藥品收入將超越其特瑞普利單抗藥品,料特瑞普利單抗藥品收入將於2024年達高峯,錄約50億元人民幣,亦認為公司股價亦未完全反映公司的發展潛力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account